Proteasome inhibitor bortezomib overcomes P‐gp‐mediated multidrug resistance in resistant leukemic cell lines

Introduction:  To study the effect of bortezomib alone or in combination with daunorubicin (DNR) on an mdr1 single‐factor drug‐resistant leukemia cell line K562/MDR1, a multifactor‐resistant cell line K562/A02, a drug‐sensitive cell line K562, and primary cells from acute myeloid leukemia patients.

[1]  Ø. Bruserud,et al.  Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia – the biological heterogeneity , 2010, Expert opinion on therapeutic targets.

[2]  M. Breccia,et al.  NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia , 2010, Expert opinion on therapeutic targets.

[3]  Jun Yu Li,et al.  The effects of proteasome inhibitor bortezomib on a P‐gp positive leukemia cell line K562/A02 , 2010, International journal of laboratory hematology.

[4]  W. Meng,et al.  Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1. , 2009, Leukemia research.

[5]  P. Chaudhary,et al.  Proteasome inhibitor Bortezomib induces cell-cycle arrest and apoptosis in cell lines derived from Ewing’s sarcoma family of tumors and synergizes with TRAIL , 2008, Cancer biology & therapy.

[6]  H. Tilg,et al.  Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. , 2007, Biochemical and biophysical research communications.

[7]  D. Fennell,et al.  BCL-2 family regulation by the 20S proteasome inhibitor bortezomib , 2007, Oncogene.

[8]  D. Germain,et al.  Targeting the ubiquitin-proteasome pathway in cancer therapy. , 2007, Anti-cancer agents in medicinal chemistry.

[9]  Ø. Bruserud,et al.  The proteasome inhibitors bortezomib and PR‐171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells , 2007, British journal of haematology.

[10]  J. Leonard,et al.  Proteasome inhibition with bortezomib: A new therapeutic strategy for non‐Hodgkin's lymphoma , 2006, International journal of cancer.

[11]  S. Plon,et al.  Bortezomib interactions with chemotherapy agents in acute leukemia in vitro , 2006, Cancer Chemotherapy and Pharmacology.

[12]  G. Morgan,et al.  Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy , 2005, Cancer Cell International.

[13]  P. Amrein,et al.  In Vitro Studies of Bortezomib with Daunorubicin and Cytarabine:Sequence of Administration Affects Leukemia Cell Chemosensitivity. , 2004 .

[14]  Hui Peng,et al.  [Identification of differentially expressed genes involved in multidrug resistance in K562/A02 by cDNA microarray]. , 2004, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[15]  D. Wolf,et al.  The ubiquitin-proteasome system: past, present and future. , 2004, Cellular and molecular life sciences : CMLS.

[16]  K. Anderson,et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.

[17]  P. Elliott,et al.  Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  J. Marie.  Drug resistance in hematologic malignancies , 2001, Current opinion in oncology.

[19]  P. Richardson,et al.  TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. , 2001, Blood.

[20]  T. Motoji,et al.  Multidrug resistance of acute leukemia and a strategy to overcome it. , 2000, International journal of hematology.

[21]  Y. Wang,et al.  Identification of the subcellular localization of daunorubicin in multidrug-resistant K562 cell line. , 2000, Leukemia research.

[22]  T. Hotta,et al.  Competitive reverse transcription-polymerase chain reaction assay for quantification of human multidrug resistance 1 (MDR1) gene expression in fresh leukemic cells. , 2000, The Journal of laboratory and clinical medicine.

[23]  J. Jaffrezou,et al.  Verapamil decreases P‐glycoprotein expression in multidrug‐resistant human leukemic cell lines , 1994, International journal of cancer.

[24]  I. Pastan,et al.  Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. , 1987, The Journal of biological chemistry.

[25]  G. Yanik,et al.  Bortezomib as a therapeutic candidate for neuroblastoma. , 2008, Journal of experimental therapeutics & oncology.

[26]  O. Sezer,et al.  The potential of proteasome inhibitors in cancer therapy. , 2008, Expert opinion on investigational drugs.

[27]  W. Dalton,et al.  The proteasome. , 2004, Seminars in oncology.